Premium
Association between the oxidative polymorphism and early onset of Parkinson's disease
Author(s) -
Agúndez José A. G.,
JiménezJiménez Félix J.,
Luengo Antonio,
Bernal María L.,
Molina José A.,
Ayuso Lucía,
Vázquez Antonio,
Parra Jaime,
Duarte Jacinto,
Coria Francisco,
Ladero José M.,
Alvarez José C.,
Benítez Julio
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90154-x
Subject(s) - genotype , parkinson's disease , cyp2d6 , medicine , disease , gastroenterology , polymorphism (computer science) , age of onset , allele , allele frequency , biology , genetics , gene
The frequency of five cytochrome P450IID6 allelic variants was studied in deoxyribonucleic acid from 123 patients with Parkinson's disease and 150 healthy volunteers. This was chieved by the use of mutation‐specific polymerase chain reaction and restriction fragment length polymorphism. The analyses of the CYP2D6 genotype revealed no evidence for a higher prevalence of poor metabolizers among patients with Parkinson's disease. However, increased frequency of patients with Parkinson's disease with the genotype CYP2D6wt/CYP2D6B was observed. This is attributable exclusively to subjects with early onset of the disease (28 to 49 years), with a relative risk ratio of 4.16 (95% confidence limits, 2.0 to 8.3; p < 0.0005). The subjects who had late‐onset Parkinson's disease (≥50 years) had genotypes and CYP2D6 allele frequencies similar to the healthy subjects. This indicates that the oxidative polymorphism is related to early‐onset but not to late‐onset Parkinson's disease. A different influence of CYP2D6 genotype on the risk of development of Parkinson's disease is observed in Spaniards, compared with previous findings in British subjects. These results suggest the combined effect of environmental toxins and CYP2D6 in the cause of Parkinson's disease. Clinical Pharmacology & Therapeutics (1995) 57 , 291–298; doi: